HK1251512A1 - 靶向蛋白造影劑、其製備方法及用途 - Google Patents

靶向蛋白造影劑、其製備方法及用途

Info

Publication number
HK1251512A1
HK1251512A1 HK18111163.8A HK18111163A HK1251512A1 HK 1251512 A1 HK1251512 A1 HK 1251512A1 HK 18111163 A HK18111163 A HK 18111163A HK 1251512 A1 HK1251512 A1 HK 1251512A1
Authority
HK
Hong Kong
Prior art keywords
making
methods
contrast agents
targeted protein
protein contrast
Prior art date
Application number
HK18111163.8A
Other languages
English (en)
Inventor
詹妮‧傑‧楊
朴凡
薛勝輝
喬景娟
譚珊珊
馬尼‧賽拉睿
Original Assignee
佐治亞州立大學研究基金會公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 佐治亞州立大學研究基金會公司 filed Critical 佐治亞州立大學研究基金會公司
Publication of HK1251512A1 publication Critical patent/HK1251512A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G99/00—Subject matter not provided for in other groups of this subclass
    • C01G99/006—Compounds containing, besides a metal not provided for elsewhere in this subclass, two or more other elements other than oxygen or hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
HK18111163.8A 2015-05-11 2018-08-30 靶向蛋白造影劑、其製備方法及用途 HK1251512A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562159685P 2015-05-11 2015-05-11

Publications (1)

Publication Number Publication Date
HK1251512A1 true HK1251512A1 (zh) 2019-02-01

Family

ID=57249507

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111163.8A HK1251512A1 (zh) 2015-05-11 2018-08-30 靶向蛋白造影劑、其製備方法及用途

Country Status (6)

Country Link
US (4) US10814020B2 (zh)
EP (1) EP3295175A4 (zh)
CN (1) CN107850590A (zh)
CA (1) CA2985075A1 (zh)
HK (1) HK1251512A1 (zh)
WO (1) WO2016183223A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3295175A4 (en) * 2015-05-11 2018-12-26 Georgia State University Research Foundation, Inc. Targeted protein contrast agents, methods of making, and uses thereof
CN107952084A (zh) * 2017-12-21 2018-04-24 同济大学 一种以人体内源性蛋白为螯合剂的磁共振造影剂及其制备
WO2020030954A1 (en) * 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
WO2020039410A1 (en) * 2018-08-24 2020-02-27 Symthera Canada Ltd. Calcium regulated binding agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369056A1 (en) 2000-02-03 2001-08-09 Thomas Jefferson University Vmip-ii peptide antagonists of cxcr4
US20050250700A1 (en) 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
DE102004061348B4 (de) * 2004-12-20 2009-03-12 Siemens Ag Verfahren zur Auswahl eines geeigneten Kontrastmittels
EP3378496A1 (en) * 2005-07-13 2018-09-26 Georgia State University Research Foundation, Inc. Contrast agents and methods for preparing contrast agents
CN101304767A (zh) * 2005-09-09 2008-11-12 佐治亚州立大学研究基金会 靶向显像剂及显像剂靶向定位的方法
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
JP5350257B2 (ja) * 2006-11-02 2013-11-27 ベリデックス・エルエルシー 免疫磁気ｍｒｉ造影剤を用いた活性化された血管内皮の画像化
EP2268317B1 (en) * 2008-03-14 2020-02-26 VisEn Medical, Inc. Integrin targeting agents and in vivo and in vitro imaging methods using the same
US20110097742A1 (en) * 2008-04-02 2011-04-28 Jenny Jie Yang Contrast agents, methods for preparing contrast agents, and methods of imaging
US9956304B2 (en) * 2012-06-05 2018-05-01 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
EP3295175A4 (en) * 2015-05-11 2018-12-26 Georgia State University Research Foundation, Inc. Targeted protein contrast agents, methods of making, and uses thereof

Also Published As

Publication number Publication date
CA2985075A1 (en) 2016-11-17
US20200397925A1 (en) 2020-12-24
US20210038746A1 (en) 2021-02-11
US11426471B2 (en) 2022-08-30
US20230057249A1 (en) 2023-02-23
CN107850590A (zh) 2018-03-27
US20180280544A1 (en) 2018-10-04
US10814020B2 (en) 2020-10-27
US11419954B2 (en) 2022-08-23
EP3295175A2 (en) 2018-03-21
WO2016183223A3 (en) 2016-12-29
EP3295175A4 (en) 2018-12-26
WO2016183223A2 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
HK1249058A1 (zh) 用於增强靶向蛋白質降解的化合物和方法
ZA201907054B (en) Anti-tau antibodies and methods of use
HK1250036A1 (zh) 抗cd 166抗體，可活化抗cd 166抗體及其使用方法
HK1250037A1 (zh) 抗-itga3抗體、可活化的抗-itga3抗體、及其使用方法
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
IL259495A (en) Antibodies and methods for using them
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
IL254458B (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies and methods of using them
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
IL268346A (en) Targeted chimeric proteins and their uses
GB201512203D0 (en) Agents,uses and methods
IL270793A (en) Anti-HTRA1 antibodies and methods of using them
HK1247091A1 (zh) 治療抗體及其用途
HK1251512A1 (zh) 靶向蛋白造影劑、其製備方法及用途
GB201512215D0 (en) Agents,uses and methods
IL267589A (en) adam9 binding molecules and methods for their use
GB201518375D0 (en) Agents,uses and methods
GB201512211D0 (en) Agents, uses and methods
GB201512216D0 (en) Agents uses and methods